Peripherally acting opioid compounds

1. A method for treating pain comprising the step of administering a compound of Formula I, or a pharmaceutically acceptable salt thereof, or Formula II to a subject in need thereof:

Wherein:

u is 0, 1 or 2;

t is 0, 1, 2, 3, 4, 5, 6, or 7;

X is S or O;

Y ⊖ is a pharmaceutically acceptable counterion;

R 1 is selected from aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl or substituted heterocyclyl;

Each R 2 , R 3 , R 4 , R 6 , R 8 , and R 11 is independently selected from hydrogen, halogen, —OR 20 , —SR 20 , —NR 20 R 21 , —C(O)R 20 , —C(O)OR 20 , —C(O)NR 20 R 21 , —N(R 20 )C(O)R 21 , —CF 3 , —CN, —NO 2 , —N 3 , acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, alkylthio, substituted alkylthio, alkylsulfonyl, substituted alkylsulfonyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl or substituted heterocyclyl; alternatively R 2 and R 3 together with the carbon they are attached to form a C═X group or a vinyl group; alternatively, two R 11 groups together with the carbon atom to which they are attached form a C═X or a vinyl group;

wherein each R 20 and R 21 is independently selected from hydrogen, halogen, alkyl, substituted alkyl, aryl or substituted aryl;

R 5 is alkyl, substituted alkyl, aryl or substituted aryl;

R 7 is hydrogen alkyl, substituted alkyl, aryl or substituted aryl;

R 9 is selected from hydrogen, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl or substituted heterocyclyl; and

R 10 is selected from Table A:

wherein s is 0, 1, 2, or 3;

p is 0, 1, 2, 3, 4, 5, 6, or 7;

q is 0, 1, 2, 3, 4, or 5;

each R 100 , R 101 , R 102 , R 103 , R 104 , and R 105 is independently selected from hydrogen, halogen, —OR 20 , —SR 20 , —NR 20 R 21 , —C(O)R 20 , —C(O)OR 20 , —C(O)NR 20 R 21 , —N(R 20 )C(O)R 21 , —CF 3 , —CN, —NO 2 , —N 3 , acyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfonyl, optionally substituted aliphatic, optionally substituted aryl, heterocyclyl or substituted heterocyclyl;

wherein the term “substituted” refers to the replacement of one or more hydrogen radicals in a given structure with the radical selected from halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, heteroaryl, and aliphatic.

2. The method according to claim 1 , wherein said compound is a mu receptor agonist.

3. The method according to claim 1 , wherein said pain is selected from inflammatory pain, centrally mediated pain, peripherally mediated pain, visceral pain, structural related pain, cancer pain, soft tissue injury related pain, progressive disease related pain, neuropathic pain and acute pain from acute injury, acute pain from trauma, acute pain from surgery, chronic pain from headache, chronic pain from neuropathic conditions, chronic pain from post-stroke conditions and chronic pain from migraine.

4. The method according to claim 1 , wherein said pain is associated with osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite, spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, cellulitis, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, post-operative ileus, cholecystitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, post-herpetic neuralgia, trigeminal neuralgia, cluster headache, migraine headache, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, inflammatory bowel disease, irritable bowel syndrome, sinus headache, tension headache, labor, childbirth, menstrual cramps, and cancer.

5. The method according to claim 1 , wherein said pain is associated with arthritis.

6. The method according to claim 5 , wherein said arthritis is selected from rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, juvenile arthritis, scapulohumeral periarthritis.

7. The method according to claim 2 , wherein the compound does not substantially cross the blood-brain barrier.

8. The method according to claim 1 , wherein said compound of Formula I is selected from:

or a pharmaceutically acceptable salt thereof.

9. A method for treating pain by modulating the activity of an opioid receptor(s) comprising the step of administering a compound to a subject in need thereof wherein said compound is selected from:

or a pharmaceutically acceptable salt thereof.

10. The method according to claim 1 , wherein R 10 is selected from below:

11. The method according to claim 1 , wherein R 10 is selected from the table below:

12. The method according to claim 1 , wherein said compound of Formula I is selected from:

or a pharmaceutically acceptable salt thereof.